Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day

Detalhes bibliográficos
Autor(a) principal: Mello Ayres Putinatti, Maria Stella de [UNESP]
Data de Publicação: 2014
Outros Autores: Lastoria, Joel Carlos [UNESP], Padovani, Carlos Roberto [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1590/abd1806-4841.20142037
http://hdl.handle.net/11449/111183
Resumo: BACKGROUND: Leprosy can have its course interrupted by type 1 and 2 reactional episodes, the last named of erythema nodosum leprosum (ENL). Thalidomide has been the medication of choice for the control of ENL episodes since 1965. OBJECTIVES: These episodes can repeat and cause damages to the patient. In order to prevent these episodes, an extra dose of 100 mg/day thalidomide was used during six months, followed by a follow-up period of six more months after thalidomide discontinuation. METHODS: We included 42 patients with multibacillary (MB) leprosy who had episodes of ENL. They were male and female patients aged between 18 and 84 years. RESULTS: Of the 42 patients, 39 (92.85%) had the lepromatous form and three (7.15%) had the borderline form. We found that 100% of patients had no reactional episode during the use of the drug. During the follow-up period after thalidomide discontinuation, 33 (78.57%) patients had no reactional episode and nine (21.43%), all of them with the lepromatous form, had mild episodes, which were controlled using non-steroidal anti-inflammatory. There were no thalidomide-related side effects. CONCLUSION: A maintenance dose of 100 mg/day of thalidomide showed to be effective to prevent repeated type 2 reactional episodes of ENL.
id UNSP_f6f10d32f3b6cb76f77374b3623d0438
oai_identifier_str oai:repositorio.unesp.br:11449/111183
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/dayErythema nodosumLeprosyMedication therapy managementThalidomideBACKGROUND: Leprosy can have its course interrupted by type 1 and 2 reactional episodes, the last named of erythema nodosum leprosum (ENL). Thalidomide has been the medication of choice for the control of ENL episodes since 1965. OBJECTIVES: These episodes can repeat and cause damages to the patient. In order to prevent these episodes, an extra dose of 100 mg/day thalidomide was used during six months, followed by a follow-up period of six more months after thalidomide discontinuation. METHODS: We included 42 patients with multibacillary (MB) leprosy who had episodes of ENL. They were male and female patients aged between 18 and 84 years. RESULTS: Of the 42 patients, 39 (92.85%) had the lepromatous form and three (7.15%) had the borderline form. We found that 100% of patients had no reactional episode during the use of the drug. During the follow-up period after thalidomide discontinuation, 33 (78.57%) patients had no reactional episode and nine (21.43%), all of them with the lepromatous form, had mild episodes, which were controlled using non-steroidal anti-inflammatory. There were no thalidomide-related side effects. CONCLUSION: A maintenance dose of 100 mg/day of thalidomide showed to be effective to prevent repeated type 2 reactional episodes of ENL.Univ Estadual Paulista Julio de Mesquita Filho Un, Botucatu, SP, BrazilUniv Estadual Paulista Julio de Mesquita Filho Un, Botucatu, SP, BrazilSoc Brasileira DermatologiaUniversidade Estadual Paulista (Unesp)Mello Ayres Putinatti, Maria Stella de [UNESP]Lastoria, Joel Carlos [UNESP]Padovani, Carlos Roberto [UNESP]2014-12-03T13:07:02Z2014-12-03T13:07:02Z2014-03-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article266-272application/pdfhttp://dx.doi.org/10.1590/abd1806-4841.20142037Anais Brasileiros De Dermatologia. Rio De Janeiro Rj: Soc Brasileira Dermatologia, v. 89, n. 2, p. 266-272, 2014.0365-0596http://hdl.handle.net/11449/11118310.1590/abd1806-4841.20142037S0365-05962014000200266WOS:000335171600009S0365-05962014000200266.pdf87278970805222899531498781164017Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengAnais Brasileiros de Dermatologia0.8840,520info:eu-repo/semantics/openAccess2024-08-14T18:46:09Zoai:repositorio.unesp.br:11449/111183Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T18:46:09Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
title Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
spellingShingle Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
Mello Ayres Putinatti, Maria Stella de [UNESP]
Erythema nodosum
Leprosy
Medication therapy management
Thalidomide
title_short Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
title_full Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
title_fullStr Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
title_full_unstemmed Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
title_sort Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
author Mello Ayres Putinatti, Maria Stella de [UNESP]
author_facet Mello Ayres Putinatti, Maria Stella de [UNESP]
Lastoria, Joel Carlos [UNESP]
Padovani, Carlos Roberto [UNESP]
author_role author
author2 Lastoria, Joel Carlos [UNESP]
Padovani, Carlos Roberto [UNESP]
author2_role author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Mello Ayres Putinatti, Maria Stella de [UNESP]
Lastoria, Joel Carlos [UNESP]
Padovani, Carlos Roberto [UNESP]
dc.subject.por.fl_str_mv Erythema nodosum
Leprosy
Medication therapy management
Thalidomide
topic Erythema nodosum
Leprosy
Medication therapy management
Thalidomide
description BACKGROUND: Leprosy can have its course interrupted by type 1 and 2 reactional episodes, the last named of erythema nodosum leprosum (ENL). Thalidomide has been the medication of choice for the control of ENL episodes since 1965. OBJECTIVES: These episodes can repeat and cause damages to the patient. In order to prevent these episodes, an extra dose of 100 mg/day thalidomide was used during six months, followed by a follow-up period of six more months after thalidomide discontinuation. METHODS: We included 42 patients with multibacillary (MB) leprosy who had episodes of ENL. They were male and female patients aged between 18 and 84 years. RESULTS: Of the 42 patients, 39 (92.85%) had the lepromatous form and three (7.15%) had the borderline form. We found that 100% of patients had no reactional episode during the use of the drug. During the follow-up period after thalidomide discontinuation, 33 (78.57%) patients had no reactional episode and nine (21.43%), all of them with the lepromatous form, had mild episodes, which were controlled using non-steroidal anti-inflammatory. There were no thalidomide-related side effects. CONCLUSION: A maintenance dose of 100 mg/day of thalidomide showed to be effective to prevent repeated type 2 reactional episodes of ENL.
publishDate 2014
dc.date.none.fl_str_mv 2014-12-03T13:07:02Z
2014-12-03T13:07:02Z
2014-03-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/abd1806-4841.20142037
Anais Brasileiros De Dermatologia. Rio De Janeiro Rj: Soc Brasileira Dermatologia, v. 89, n. 2, p. 266-272, 2014.
0365-0596
http://hdl.handle.net/11449/111183
10.1590/abd1806-4841.20142037
S0365-05962014000200266
WOS:000335171600009
S0365-05962014000200266.pdf
8727897080522289
9531498781164017
url http://dx.doi.org/10.1590/abd1806-4841.20142037
http://hdl.handle.net/11449/111183
identifier_str_mv Anais Brasileiros De Dermatologia. Rio De Janeiro Rj: Soc Brasileira Dermatologia, v. 89, n. 2, p. 266-272, 2014.
0365-0596
10.1590/abd1806-4841.20142037
S0365-05962014000200266
WOS:000335171600009
S0365-05962014000200266.pdf
8727897080522289
9531498781164017
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Anais Brasileiros de Dermatologia
0.884
0,520
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 266-272
application/pdf
dc.publisher.none.fl_str_mv Soc Brasileira Dermatologia
publisher.none.fl_str_mv Soc Brasileira Dermatologia
dc.source.none.fl_str_mv Web of Science
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128193480097792